

DAFTAR PUSTAKA

1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *Journal of Autoimmunity*. 2020;109:102433.
2. WHO. WHO Coronavirus (COVID-19) Dashboard [Internet]. 2020 [cited 2021 Jul 31]. Available from: <https://covid19.who.int/>
3. Satuan Tugas Penanganan COVID-19. Peta Sebaran COVID-19 [Internet]. 2021 [cited 2021 Jul 31]. Available from: <https://covid19.go.id/peta-sebaran-covid19>
4. TIM IT DISKOMINFO PROVINSI SUMBAR. Covid-19 di Provinsi Sumatera Barat [Internet]. 2021 [cited 2021 Jul 31]. Available from: https://corona.sumbarprov.go.id/details/peta_covid19
5. Ramatillah DL, Isnaini S. Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta. *PLoS One*. 2021;16:1–11. Available from: <http://dx.doi.org/10.1371/journal.pone.0250147>
6. Uzunova K, Filipova E, Pavlova V, Vekov T. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. *Biomedicine & Pharmacotherapy*. 2020;131:110668.
7. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D. Remdesivir for the treatment of Covid-19. *The New England Journal of Medicine*. 2020;383(19):1813–1826.
8. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *The Lancet*. 2020;395(10236):1569–1578.
9. Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo W, Susilo A. *Pedoman Tata Laksana COVID-19 4th edition*. Jakarta: PDPI PERKI PADPDI PERDATIN IDAI;2022.
10. Gao, Y. D., Ding, M., Dong, X., Zhang, J. J., Kursat Azkur, A., Azkur, D., Gan, H., Sun, Y. L., Fu, W., Li, W., Liang, H. L., Cao, Y. Y., Yan, Q., Cao, C., Gao, H. Y., Brügger, M. C., van de Veen, W., Sokolowska, M., Akdis, M., & Akdis, C. A. Risk factors for severe and critically ill COVID-19 patients. *Allergy*. 2021;76:428–455.
11. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ, Li L, Chen PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B, Xiong S, Ni ZY, Xiang J, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX. Comorbidity and its impact on

- 1590 patients with COVID-19 in China: a nationwide analysis. *European Respiratory Journal*. 2020;55(5).
12. Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. *American journal of hypertension*. 2020;33(5):373–374.
 13. Zhou X, Zhu J, Xu T. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors. *Clinical and Experimental Hypertension*. 2020;42(7):656–660.
 14. Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L, Xia M. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. *Circulation Research*. 2020;126(12):1671–1681.
 15. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. *Journal of Advanced Research*. 2020;24:91–98. Available from: <https://doi.org/10.1016/j.jare.2020.03.005>
 16. Li H, Liu S-M, Yu X-H, Tang S-L, Tang C-K. Coronavirus disease 2019 (COVID-19): current status and future perspectives. *International Journal of Antimicrobial Agents*. 2020;55(5):105951.
 17. Biryukov, J., Boydston, J. A., Dunning, R. A., Yeager, J. J., Wood, S., Ferris, A., Miller, D., Weaver, W., Zeitouni, N. E., Freeburger, D., Dabisch, P., Wahl, V., Hevey, M. C., & Altamura, L. A. SARS - CoV - 2 is rapidly inactivated at high temperature. *Environ Chem Letter*. 2021;19(2):1773–1777. Available from: <https://doi.org/10.1007/s10311-021-01187-x>
 18. Wang Z, Qiang W, Ke H. Handbook of 2019-nCoV pneumonia Control and prevention. *Hubei Science and Technology Press*. 2019; Available from: <https://zenodo.org/record/3630678>
 19. Delamater PL, Street EJ, Leslie TF, Yang YT, Jacobsen KH. Complexity of the Basic Reproduction Number (R(0)). *Emerging Infectious Diseases*. 2019;25(1):1–4.
 20. Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, Sun C, Sylvia S, Rozelle S, Raat H, Zhou H. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. *Infectious Diseases of Poverty*. 2020;(9)1:1-12.
 21. Adhikari A, Koirala S, Tiwari S, Ghimire N, Khatiwada A, Dhakal R. Features, evaluation, and treatment of COVID-19 infected patient : A case study in 31 hospitals in Nepal. *International Journal of Multidisciplinary Research and Development*. 2020;7(6):201–207. Available from: www.allsubjectjournal.com
 22. Jalava K. First respiratory transmitted food borne outbreak?. *International Journal of Hygiene and Environmental Health*. 2020;226:113490.

23. Qu J-M, Cao B, Chen R-C. *Respiratory virus and COVID-19. COVID-19 The Essentials of Prevention and Treatment*. China : Shanghai Jiao-Tong University Press; 2021.
24. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. *Postgraduated Medical Journal*. 2021;97:312-320.
25. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DS, Du B. Clinical characteristics of coronavirus disease 2019 in China. *The New England Journal of Medicine*. 2020;382(18):1708–1720.
26. Tadic M, Cuspidi C, Mancina G, Dell’Oro R, Grassi G. COVID-19, hypertension and cardiovascular diseases: Should we change the therapy? *Pharmacological Research*. 2020;158:104906.
27. Bohn MK, Hall A, Sepiashvili L, Jung B, Steele S, Adeli K. Pathophysiology of COVID-19: Mechanisms underlying disease severity and progression. *Physiology*. 2020;35(5):288–301.
28. Zhang L, Guo H. Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. *Advances in Biomarker Sciences and Technology*. 2020;2:1–23. Available from: <https://doi.org/10.1016/j.abst.2020.08.001>
29. Levani, Prastya, Mawaddatunnadila. Coronavirus Disease 2019 (COVID-19): Patogenesis, Manifestasi Klinis dan Pilihan Terapi. *Jurnal Kedokteran dan Kesehatan*. 2021;17(1):44–57.
30. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. *Journal of Pharmaceutical Analysis*. 2020;10(2):102–108. Available from: <https://doi.org/10.1016/j.jpha.2020.03.001>
31. Dhama K, Patel SK, Pathak M, Yattoo MI, Tiwari R, Malik YS. An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies. *Travel Medicine and Infectious Disease*. 2020;37:101755. Available from: <https://doi.org/10.1016/j.tmaid.2020.101755>
32. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, Zhang HY, Sun W, Wang Y. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. *Journal of medical virology*. 2020;92(6):577-583.
33. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. *Nature reviews Microbiology*. 2021;19(3):141–54. Available from: <http://dx.doi.org/10.1038/s41579-020-00459-7>
34. WHO. Coronavirus disease (COVID-19) [Internet]. 2021 [cited 2021 Sep 24]. Available from: https://www.who.int/health-topics/coronavirus#tab=tab_3
35. Burhan, E., Isbaniah, F., Susanto, A. D., Yoga, Y., Tjandra, A., Sugiri, T., & Tantular, R. *Pneumonia COVID-19 Diagnosis & Penatalaksanaan di Indonesia*. Jakarta: Perhimpunan Dokter Paru Indonesia.2020;1-49.

36. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ*. 2020;369.
37. Jin, Y., Yang, H., Ji, W., Wu, W., Chen, S., Zhang, W., & Duan, G. Virology, epidemiology, pathogenesis, and control of COVID-19. *Viruses*. 2020;12(4):1–17.
38. WHO. Hypertension [Internet]. 2021 [cited 2021 Sep 17]. Available from: <https://www.who.int/news-room/fact-sheets/detail/hypertension>
39. T. DiPiro J, C.Yee G, Posey LM, T.Haines S, D. Nolin T, Ellingrod V. *Pharmacotherapy: A Pathophysiologic Approach 11 th Ed.* Weitz M, J.Boyle P, editors. United States Of America: McGraw Hill; 2020.
40. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D. International Society of Hypertension Global Hypertension Practice Guidelines. *Hypertension*. 2020;75(6):1334–1357.
41. Kadir A. Hubungan patofisiologi hipertensi dan hipertensi renal. *Jurnal Ilmiah Kedokteran Wijaya Kusuma*. 2018;5(1):15-25.
42. NCD Risk Factor Collaboration (NCD-RiSc). Articles Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 : a pooled analysis of 1201 population-representative studies with 104 million participants. *The Lancet*. 2021;398:967-980.
43. Kementerian Kesehatan Republik Indonesia. *Profil Kesehatan Indonesia 2019*. Jakarta: Kemenkes RI; 2020.
44. World Health Organization. *A global brief on hypertension: silent killer, global public health crisis: World Health Day 2013*. World Health Organization; 2013.
45. Kementerian Kesehatan Republik Indonesia. *Infodatin hipertensi si pembunuh senyap*. Kemenkes RI; 2019:1–10.
46. PERHIMPUNAN DOKTER HIPERTENSI INDONESIA. *Penatalaksanaan hipertensi J 2021: A Update Konsensus PERHI 2019*. Jakarta: 2021.
47. Mubarik S, Liu X, Eshak ES, Liu K, Liu Q. The Association of Hypertension With the Severity of and Mortality From the COVID-19 in the Early Stage of the Epidemic in Wuhan, China: A Multicenter Retrospective Cohort Study. *Frontiers in medicine*. 2021;8:623608.
48. Alfhad H, Saftarina F, Kurniawan B. The Impact of SARS-Cov-2 infection on patients with hypertension. *Majority Journal*. 2020;9(1):1–5.
49. Kulkarni S, Jenner BL, Wilkinson I. COVID-19 and hypertension. *JRAAS - Journal of the Renin-Angiotensin-Aldosterone System*. 2020;21(2).
50. Maturroh I, Anggita NT. *Metodologi Penelitian Kesehatan*. Jakarta; 2018.
51. Daniel WW, CL C. *BIostatistics Tenth*. New York: A Foundation for Analysis in the Health Science; 2019.

52. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, Liu S, Yang JK. Gender Differences in Patients With COVID-19 : Focus on Severity and Mortality. *Frontiers in public health*. 2020;8(152):1–6.
53. Faustine I, Malik A, Andrajati R, Wanandi SI. Clinical Characteristics and Severity Profile of COVID-19 Patient with Hypertension in Palu, Central Sulawesi. *Indonesian Journal of Pharmacy*. 2021;32(4):563–572.
54. Ambrosino, I., Barbagelata, E., Ortona, E., Ruggieri, A., Massiah, G., Giannico, O. V., Politi, C., & Moretti, A. M. Gender differences in patients with COVID-19: A narrative review. *Monaldi archives for chest disease*. 2020;90(2):318–324.
55. Huang S, Wang J, Liu F, Liu J, Cao G, Yang C. COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. *Hypertension Research*. 2020;43(8):824–831. Available from: <http://dx.doi.org/10.1038/s41440-020-0485-2>
56. Fortunato, F., Martinelli, D., Lo Caputo, S., Santantonio, T., Dattoli, V., Lopalco, P. L., & Prato, R. Sex and gender differences in 19: an Italian local register-based study. *BMJ open*. 2021;11(10):1–7.
57. Andasari SD, Kasjono HS. Diagnosis and epidemiology of Coronavirus (COVID-19) outbreak in Indonesia. *Jurnal Teknologi Laboratorium*. 2020;9(1):49–56.
58. Kurniati R, Abdullah F, Kam A. The Profile of COVID-19 Patients in Semen Padang Hospital Indonesia. *Andalas Journal of Health*. 2021;10(1):45-48.
59. Baihaqi FA, Rumaropen H. Factors Associated with Length of Stay of COVID-19 Patients at Serui Regional General Hospital Papua Province: Cross-Sectional Study. *Jurnal Penyakit Dalam Indonesia*. 2021;8(4):187–194.
60. Luo H, Liu S, Wang Y, Phillips-Howard PA, Ju S, Yang Y. Age differences in clinical features and outcomes in patients with COVID-19, Jiangsu, China: A retrospective, multicentre cohort study. *BMJ Open*. 2020;10(10).
61. Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients with COVID-19 and Hypertension: A Single-Center Retrospective Study. *Hypertension*. 2020;76(1):51–8.
62. Fata UH, Febriana L. Oxygen Saturation (SPO2) in Covid-19 Patients. *Journal of Ners and Midwifery*. 2021;8(3):290–294.
62. Ariyani H, Fitriani S, Rahmah S. Profil Penggunaan Obat pada Pasien COVID-19 di Rumah Sakit Umum Daerah Ulin Banjarmasin. *Journal Pharmascience*. 2021;8(2):133–148.
64. Jang SY, Seon JY, Yoon SJ, Park SY, Lee SH, Oh IH. Comorbidities and factors determining medical expenses and length of stay for admitteccovid-

- 19 patients in Korea. *Risk Management and Healthcare Policy*. 2021;14:2021–2033.
65. Tan, J., Yuan, Y., Xu, C., Song, C., Liu, D., Ma, D., & Gao, Q. A retrospective comparison of drugs against COVID-19. *Virus Research*. 2021;294.
 66. Chiam, T., Subedi, K., Chen, D., Best, E., Bianco, F. B., Dobler, G., & Papas, M. (2021). Hospital length of stay among COVID-19-positive patients. *Journal of clinical and translational research*. 2021;7:377–385.
 67. Rees, E. M., Nightingale, E. S., Jafari, Y., Waterlow, N. R., Clifford, S., B Pearson, C. A., Group, C. W., Jombart, T., Procter, S. R., & Knight, G. M. COVID-19 length of hospital stay: a systematic review and data synthesis. *BMC medicine*. 2020;18(1):270. Available from: <https://doi.org/10.1186/s12916-020-01726-3>
 68. Hu J, Zhang X, Zhang X, Zhao H, Lian J, Hao S, Jia H, Yang M, Lu Y, Xiang D, Cai H. COVID-19 is more severe in patients with hypertension; ACEI/ARB treatment does not influence clinical severity and outcome. *The Journal of infection*. 2020;8(6): 979–997.
 69. Deng W, Yang C, Yang S, Chen H, Qiu Z, Chen J. Evaluation of favipiravir in the treatment of COVID-19 based on the real-world. *Expert review of anti-infective therapy*. 2022;20(4):555–565 Available from: <https://doi.org/10.1080/14787210.2022.2012155>
 70. Shinkai, M., Tsushima, K., Tanaka, S., Hagiwara, E., Tarumoto, N., Kawada, I., Hirai, Y., Fujiwara, S., Komase, Y., Saraya, T., Koh, H., Kagiya, N., Shimada, M., Kanou, D., Antoku, S., Uchida, Y., Tokue, Y., Takamori, M., Gon, Y., Ie, K., ... Iwata, S. Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial. *Infectious diseases and therapy*. 2021;10(4):2489–2509. Available from: <https://doi.org/10.1007/s40121-021-00517-4>
 71. Marliana L, Marliani L. Analisis Perbandingan Lama Rawat Inap Pasien Terdiagnosis Covid-19 Antara Pemberian Terapi Oseltamivir Dengan Favipiravir di RSUD R.Syamsudin S.H Sukabumi Periode Mei s.d Juli 2021. *Jurnal Sosial dan Sains*. 2021;1(11):1413–1422.
 72. Damayanti H, Sajinadiyasa IGK, Risni HW, Sauriasari R. The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali, Indonesia. *National Public Health Journal*. 2021;16(4):289–297.
 73. Reule S, Drawz PE. Heart rate and blood pressure: any possible implications for management of hypertension?. *Current hypertension reports*. 2012;14(6):478–484. Available from: <https://pubmed.ncbi.nlm.nih.gov/22972532>
 74. Maloberti, A., Ughi, N., Bernasconi, D. P., Rebora, P., Cartella, I., Grasso, E., Lenoci, D., Del Gaudio, F., Algeri, M., Scarpellini, S., Perna, E., Verde,

- A., Santolamazza, C., Vicari, F., Frigerio, M., Alberti, A., Valsecchi, M. G., Rossetti, C., Epis, O. M., Giannattasio, C., ... On The Behalf Of The Niguarda Covid-Working Group. Heart Rate in Patients with SARS-CoV-2 Infection: Prevalence of High Values at Discharge and Relationship with Disease Severity. *Journal of clinical medicine*. 2021;10(23),5590. Available from: <https://doi.org/10.3390/jcm10235590>
75. Brunetti, N. D., Polisenò, M., Bottalico, I. F., Centola, A., Montemurro, L., Sica, S., Santantonio, T., & Lo Caputo, S. Safety and heart rate changes in Covid-19 patients treated with Remdesivir. *International journal of infectious diseases*. 2021;112:254–257. Available from: <https://doi.org/10.1016/j.ijid.2021.09.036>
 76. Bowring, M. G., Wang, Z., Xu, Y., Betz, J., Muschelli, J., Garibaldi, B. T., & Zeger, S. L. Outcome-Stratified Analysis of Biomarker Trajectories for Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2. *American journal of epidemiology*. 2021;190(10):2094–2106. Available from: <https://doi.org/10.1093/aje/kwab138>
 77. Liu, W., Tao, Z. W., Wang, L., Yuan, M. L., Liu, K., Zhou, L., Wei, S., Deng, Y., Liu, J., Liu, H. G., Yang, M., & Hu, Y. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. *Chinese medical journal*. 2020;133(9):1032–1038. Available from: <https://doi.org/10.1097/CM9.0000000000000775>
 78. Karya, K., Suwidnya, I., Wijaya B. Hubungan penyakit komorbiditas terhadap derajat klinis COVID-19. *Intisari Sains Medis*. 2021;12(2):708–717.
 79. Manabe T, Kambayashi D, Akatsu H, Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. *BMC infectious diseases*. 2021;21(1):1–13.
 80. Spinner, C. D., Gottlieb, R. L., Criner, G. J., Arribas López, J. R., Cattelan, A. M., Soriano Viladomiu, A., Ogbuagu, O., Malhotra, P., Mullane, K. M., Castagna, A., Chai, L., Roestenberg, M., Tsang, O., Bernasconi, E., Le Turnier, P., Chang, S. C., SenGupta, D., Hyland, R. H., Osinusi, A. O., Cao, H., Investigators. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. *JAMA*. 2020;324(11):1048–1057. Available from: <https://doi.org/10.1001/jama.2020.16349>
 81. Goldman JD, Lye DC, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD, Galli M, Ahn MY, Nahass RG, Chen YS. Remdesivir for 5 or 10 days in patients with severe Covid-19. *The New England Journal of Medicine*. 2020;383(19):1827–1837. Available from: <https://doi.org/10.1056/NEJMoa2015301>
 82. Tharakan S, Nomoto K, Miyashita S, Ishikawa K. Body temperature correlates with mortality in COVID-19 patients. *Critical care*. 2020;24(1):298
 83. Fang H, Liu Q, Xi M, Xiong D, He J, Luo P, Li Z. Impact of comorbidities

on clinical prognosis in 1280 patients with different types of COVID-19 *Journal of Investigative Medicine*. 2021;69(1):75-85

84. Doi, Y., Hibino, M., Hase, R., Yamamoto, M., Kasamatsu, Y., Hirose, M., Mutoh, Y., Homma, Y., Terada, M., Ogawa, T., Kashizaki, F., Yokoyama, T., Koba, H., Kasahara, H., Yokota, K., Kato, H., Yoshida, J., Kita, T., Kato, Y., Kamio, T., Kondo, M. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. *Antimicrobial agents and chemotherapy*. 2020;64(12):1-9. Available from: <https://doi.org/10.1128/AAC.01897-20>
85. Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., Luo, Y., Ju, L., Zhang, J., & Wang, X. Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. *Frontiers in pharmacology*. 2021;12:2292 Available from: <https://doi.org/10.3389/fphar.2021.683296>
86. Fadlilah S, Rahil NH, Lanni F. Analisis Faktor yang Mempengaruhi Tekanan Darah dan Saturasi Oksigen Perifer (SpO2). *Jurnal Kesehatan Kusuma Husada*. 2020;11(1):21–30.
87. Dabbous, H. M., El-Sayed, M. H., El Assal, G., Elghazaly, H., Ebeid, F., Sherief, A. F., Elgaafary, M., Fawzy, E., Hassany, S. M., Riad, A. R., & TagelDin, M. A. Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. *Scientific reports*. 2021;11(1):7282. Available from: <https://doi.org/10.1038/s41598-021-85227-0>

